{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Group+B", "query": { "intervention": "Placebo Group B" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 807, "total_pages": 81, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Group+B&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T08:38:43.237Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07525544", "title": "A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4770359", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 214, "start_date": "2026-05-14", "completion_date": "2027-05-05", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07525544" }, { "nct_id": "NCT05516498", "title": "Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cirrhosis" ], "interventions": [ { "name": "Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)", "type": "DRUG" }, { "name": "Part A: zibotentan (dose B) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)", "type": "DRUG" }, { "name": "Part B: placebo (matching zibotentan capsule) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: zibotentan (dose A) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: zibotentan (dose B) + dapagliflozin", "type": "DRUG" }, { "name": "Part B: zibotentan (dose C) + dapagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 205, "start_date": "2022-10-31", "completion_date": "2025-07-17", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05516498" }, { "nct_id": "NCT00128193", "title": "Leprosy Skin Test Antigens Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leprosy" ], "interventions": [ { "name": "Tuberculin, Purified Protein Derivative", "type": "BIOLOGICAL" }, { "name": "MLSA-LAM", "type": "OTHER" }, { "name": "MLCwA", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 260, "start_date": "2002-04", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2014-12-24", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 1, "location_summary": "Fort Collins, Colorado", "locations": [ { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00128193" }, { "nct_id": "NCT01150695", "title": "Phase II Tularemia Vaccine Comparison", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tularaemia" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Undiluted Francisella tularensis live attenuated vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 228, "start_date": "2010-09", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-01-13", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 5, "location_summary": "Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01150695" }, { "nct_id": "NCT03446456", "title": "Vasopressin and Pain Perception in the Brain", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Pain" ], "interventions": [ { "name": "Arginine vasopressin", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" }, { "name": "Observational learning", "type": "BEHAVIORAL" }, { "name": "fMRI data aquisition", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-09-17", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446456" }, { "nct_id": "NCT04002934", "title": "Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis", "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Bazedoxifene Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Riley Bove, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "40 Years to 65 Years · Female only" }, "enrollment_count": 63, "start_date": "2019-09-10", "completion_date": "2025-05-20", "has_results": false, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04002934" }, { "nct_id": "NCT04233034", "title": "Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type1 Diabetes" ], "interventions": [ { "name": "HCL", "type": "DEVICE" }, { "name": "verapamil 120mg tablet", "type": "DRUG" }, { "name": "non-HCL", "type": "DEVICE" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Jaeb Center for Health Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Years to 17 Years" }, "enrollment_count": 113, "start_date": "2020-07-09", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 6, "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04233034" }, { "nct_id": "NCT04966871", "title": "Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria" ], "interventions": [ { "name": "PfSPZ Vaccine", "type": "BIOLOGICAL" }, { "name": "PfSPZ Challenge (7G8) for CHMI", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sanaria Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 54, "start_date": "2021-09-27", "completion_date": "2022-06-21", "has_results": false, "last_update_posted_date": "2022-07-18", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04966871" }, { "nct_id": "NCT07141199", "title": "A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ABBV-8736", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2025-09-02", "completion_date": "2026-03-23", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07141199" }, { "nct_id": "NCT06605599", "title": "Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bipolar I Disorder", "Bipolar II Disorder" ], "interventions": [ { "name": "ABBV-932", "type": "DRUG" }, { "name": "Placebo for ABBV-932", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 161, "start_date": "2024-10-15", "completion_date": "2025-12-10", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-09-10T08:38:43.237Z", "location_count": 32, "location_summary": "Dothan, Alabama • Anaheim, California • Colton, California + 28 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Colton", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Imperial", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06605599" } ] }